Trial Profile

A Phase 1b CX-2051 combination study with bevacizumab in earlier lines of CRC therapy.

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 30 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; CX 2051 (Primary)
Indications Colorectal cancer
Focus Adverse reactions

Most Recent Events

08 Jan 2026 According to the CytomX Therapeutics media release, initial data is expected by first half of 2027.
03 Dec 2025 New trial record
06 Nov 2025 According to the CytomX Therapeutics media release, company expected to start this trial in Q1 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com